<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012153</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-Tx tolerance</org_study_id>
    <secondary_id>2013-003221-29</secondary_id>
    <nct_id>NCT02012153</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stromal Cells in Kidney Transplant Recipients</brief_title>
  <official_title>AUTOLOGOUS MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general aim of the present study is to test a cell therapy with autologous ex-vivo
      expanded mesenchymal stromal cells (MSCs) as a strategy to induce tolerance in living-donor
      kidney transplant recipients. MSCs will be prepared accordingly to established protocols,
      starting from bone marrow explants of living-donor kidney transplant recipients obtained 3-4
      months before kidney transplant. From these samples, MSCs will be expanded in Good
      Manufacturing Practice (GMP) approved facilities and used for the present study in patients
      undergoing kidney transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating na√Øve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).</measure>
    <time_frame>Changes from baseline at 6 and 12 months after transplant.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T-cell function by ELISPOT assay in mixed lymphocyte reaction.</measure>
    <time_frame>Changes from baseline at 6 and 12 months after transplant.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events.</measure>
    <time_frame>Changes from baseline up to 48 months.</time_frame>
    <description>At each visit the overall clinical condition of the patient will be evaluated and any adverse event will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating regulatory T cell count.</measure>
    <time_frame>Changes from baseline at 6 and 12 months after transplant.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR.</measure>
    <time_frame>Changes from baseline at 6 and 12 months after transplant.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stromal Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.
2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stromal Cells</intervention_name>
    <arm_group_label>Mesenchymal Stromal Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients;

          -  Aged 18 or older;

          -  Living-donor (related and unrelated, spouse/husband) kidney transplant recipients;

          -  Non-Human Leukocyte Antigen (HLA) identical with the donor (one or two haplotype
             mismatches);

          -  First kidney transplant;

          -  Capable of understanding the purpose and risk of the study;

          -  Written informed consent.

        Exclusion Criteria:

          -  MSC donor positive for HIV-1, HIV-2, hepatitis B virus (HBV),hepatitis C virus (HCV),
             syphilis;

          -  Specific contraindication to MSC infusion;

          -  Any clinical relevant condition that might affect study participation and/or study
             results;

          -  Pregnant women and nursing mothers;

          -  Unwillingness or inability to follow study protocol in the investigator's opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Remuzzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norberto Perico, MD</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Di Ricerche Farmacologiche Mario Negri</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Rota, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Federica Casiraghi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Di Ricerche Farmacologiche Mario Negri</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martino Introna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratorio G. Lanzani, Bergamo, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Rambaldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Norberto Perico, MD</last_name>
    <phone>0039 035 45351</phone>
    <email>norberto.perico@marionegri.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>U.O. Nefrologia e Dialisi</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Ruggenenti, MD</last_name>
      <phone>0039 035 2674037</phone>
      <email>pruggenenti@hpg23.it</email>
    </contact>
    <investigator>
      <last_name>Eliana Gotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Tolerance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

